BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36613510)

  • 21. Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells.
    Duarte D; Rêma A; Amorim I; Vale N
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2007; 12(1):71-6. PubMed ID: 17436405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L-Canavanine Potentiates Cytotoxicity of Chemotherapeutic Drugs in Human Breast Cancer Cells.
    Nurcahyanti AD; Wink M
    Anticancer Agents Med Chem; 2017; 17(2):206-211. PubMed ID: 26902604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.
    Xu J; Mo Y; Wang X; Liu J; Zhang X; Wang J; Hu L; Yang C; Chen L; Wang Y
    J Gastroenterol; 2013 Feb; 48(2):203-13. PubMed ID: 22820863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment.
    Duong HH; Yung LY
    Int J Pharm; 2013 Sep; 454(1):486-95. PubMed ID: 23792465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colossolactone-G synergizes the anticancer properties of 5-fluorouracil and gemcitabine against colorectal cancer cells.
    Algehani RA; Abou Khouzam R; Hegazy GA; Alamoudi AA; El-Halawany AM; El Dine RS; Ajabnoor GA; Al-Abbasi FA; Baghdadi MA; Elsayed I; Hattori M; Al-Abd AM
    Biomed Pharmacother; 2021 Aug; 140():111730. PubMed ID: 34062410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells.
    Spina A; Sorvillo L; Chiosi E; Esposito A; Di Maiolo F; Sapio L; Caraglia M; Naviglio S
    Oncol Rep; 2013 May; 29(5):1689-96. PubMed ID: 23446517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer.
    Tong J; Xie G; He J; Li J; Pan F; Liang H
    J Biomed Biotechnol; 2011; 2011():740564. PubMed ID: 21403907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells.
    Duarte D; Guerreiro I; Vale N
    Curr Issues Mol Biol; 2022 Oct; 44(10):4930-4949. PubMed ID: 36286050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.
    Zoli W; Ulivi P; Tesei A; Fabbri F; Rosetti M; Maltoni R; Giunchi DC; Ricotti L; Brigliadori G; Vannini I; Amadori D
    Breast Cancer Res; 2005; 7(5):R681-9. PubMed ID: 16168113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
    Attoub S; Arafat K; Khalaf T; Sulaiman S; Iratni R
    Nutrients; 2018 May; 10(5):. PubMed ID: 29724012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.
    Pasquier E; Ciccolini J; Carre M; Giacometti S; Fanciullino R; Pouchy C; Montero MP; Serdjebi C; Kavallaris M; André N
    Oncotarget; 2011 Oct; 2(10):797-809. PubMed ID: 22006582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells.
    Sasaki K; Tsuno NH; Sunami E; Tsurita G; Kawai K; Okaji Y; Nishikawa T; Shuno Y; Hongo K; Hiyoshi M; Kaneko M; Kitayama J; Takahashi K; Nagawa H
    BMC Cancer; 2010 Jul; 10():370. PubMed ID: 20630104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
    Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
    Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
    Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer.
    Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A
    Bioengineered; 2022 Jan; 13(1):1942-1951. PubMed ID: 35019820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
    Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel.
    Wang L; Chen H; Wang F; Zhang X
    Expert Opin Drug Deliv; 2022 Feb; 19(2):147-161. PubMed ID: 35130795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer.
    Roque MC; Franco MS; Vilela JMC; Andrade MS; de Barros ALB; Leite EA; Oliveira MC
    Curr Drug Deliv; 2019; 16(9):829-838. PubMed ID: 31622204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.